Loading [Contrib]/a11y/accessibility-menu.js
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Cardiovascular Conditions
    • Commentary
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Hematology
    • Hereditary Genetic Disorders
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Nephrologic/Hepatologic Conditions
    • Neurological Diseases
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://jheor.org/feed
×
Oncology
Vol. 5, Issue 2, 2018 November 29, 2017 EDT

Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

María Teresa Gómez-Casares , Juan Carlos Hernández-Boluda , Antonio Jiménez-Velasco , Joaquin Martínez-López , María Giovanna Ferrario , Irmina Gozalbo , Joana Gostkorzewicz , Rudi Subirá ,
  • janus kinase (jak) inhibitor
  • splenomegaly
  • myelofibrosis
  • jakavi® (ruxolitinib)
  • cost-effectiveness
ccby-4.0 • https://doi.org/10.36469/9808
JHEOR
1.
Gómez-Casares MT, Hernández-Boluda JC, Jiménez-Velasco A, et al. Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. JHEOR. 2017;5(2):162-174. doi:10.36469/9808
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system